FWIW: I've been investing in bio for over 30 years.
The majority of drugs in clinical trials for AZ the patients and caregivers report improvements in daily activities.
We got a couple hundred shares when CTRV was spun off of SGYP.
Added over 8,000 last week. They have a drug for lupus in trials but this Hepatitis drug has more potential.
I was at the gym this morning when the news hit. Will hold now.
The drug has already had a Phase 1 so they can advance it fairly fast.
jk - Obviously you are an expert. Gee I almost fell for it!
Thank god for posters like you.
This is why I love Yahoo message boards. Guys like you can act like big shots.
Synergy Pharma rated New Buy at Rodman
Oct 1 2015, 07:50 ET | By: Eli Hoffmann, SA News Editor Contact this editor with comments or a news tip
Price-target $20 (implied upside 279%)."Synergy represents a late-stage, highly risk-mitigated and undervalued name in the biotech sector, as its lead candidate plecanatide has already completed two pivotal Phase 3 trials in chronic idiopathic constipation (CIC) successfully and is slated to be filed for approval by the end of this year.""From our perspective, Synergy possesses potentially the most favorably-positioned drug in disorders of the lower GI tract."Firm notes that Ironwood (NASDAQ:IRWD), the originator of linaclotide, trades at a $1.5B valuation, a substantial premium to the $600M market cap of Synergy, even though Ironwood does not own the full rights to its product, while Synergy retains 100% ownership of plecanatide. The two products seem to have equal efficacy, but linaclotide seems to induce a higher discontinuation rate.Over the past week, BTIG put a $11 target on SGYP, and Canaccord a $19 target.Related: Does Synergy Pharma's Plecanatide Blow Away The Competition? (Jul. 16)Related: Synergy Pharma Still Has Significant Upside Potential (Jul. 8)
I love how people come on message boards and act like they know it all.
If we knew it all we wouldn't be wasting our time posting nonsense on a Yahoo message board, would we?
SGYP appears by all accounts to have a great drug.
That's enough for a retail pissant like myself.
If you haven't noticed biotech is getting crushed and little ol Synergy doesn't have a drug approved yet. IRWD is like 40% off it's highs and you are like a total nincompooper.
Easy money? Anyone that recommended that post is naive. Nothing is guaranteed. There are a lot of posters here that were sure the company would be bought out by now.
"...a "spin off" of dolcanatide is highly highly unlikely."
I totally agree.
I'm assuming you haven't owned Synergy a long time.
Here's some Synergy history for you:
Back in Febuary 2014 Synergy spun off FV-100 assets into a newly formed subsidiary, ContraVir Pharmecuticals. There was a 100% distribution of the ContraVir shares of common stock, held by
Synergy, to Synergy's stockholders on a pro-rata basis.
It's Sept 1st. Trials often take longer than anticipated to fully enroll. I wouldn't get too nervous yet but I'm not you. The CIC Phase 3 results were later than most here predicted.
From ClinicalTrials.gov (last updated June 2015):
Estimated Enrollment: 1050
Study Start Date: December 2014
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome
The study completion date is Dec 2015. The company has said the topline data will be forthcoming late 2015/ early 2016. I have no reason to doubt them.
"China has unleashed an unprecedented package of support measures, including using state-backed entities to buy stocks and cracking down on "malicious" short-selling -- when investors sell shares they do not own in anticipation of a fall in their price."
Analyst Timothy Chiang said, "We think SGYP’s plecanatide shows promise as a future treatment for CIC and IBS-C, which is a growing market category in the US. With ~45 million Americans suffering from chronic constipation and IBS, and companies like Allergan (AGN, Not Rated) and Valeant (VRX, Buy, $290 PT) focusing their marketing efforts on GI treatments, it seems logical to imagine SGYP as a takeover candidate."